TAM
FATE icon

Tiverton Asset Management’s Fate Therapeutics FATE Stock Holding History

Tiverton Asset Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$135K Hold
8,673
– – ﹤0.01% 607
2019
Q2 		$176K Hold
8,673
– – 0.01% 567
2019
Q1 		$153K Hold
8,673
– – 0.01% 544
2018
Q4 		$111K Buy
+8,673
New +$121K 0.01% 357

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return

Tiverton Asset Management's FATE Position: Q3 2019 in Review

Tiverton Asset Management held its Fate Therapeutics (FATE) position steady in Q3 2019 at 8,673 shares worth $135K. The position accounts for ﹤0.01% of the portfolio, ranked #607.

Tiverton Asset Management first reported a position in FATE in Q4 2018 and has held it in 4 quarters since. The position peaked at $176K in Q2 2019. 149 funds tracked by Wall St. Rank hold FATE as of Q3 2019.

  • Tiverton Asset Management held 8,673 shares of Fate Therapeutics worth $135K as of Q3 2019.
  • Tiverton Asset Management left its Fate Therapeutics share count unchanged in Q3 2019.
  • Fate Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #607 holding.
  • Tiverton Asset Management first reported a position in Fate Therapeutics in Q4 2018 and has held it in 4 quarters since.
  • Tiverton Asset Management's Fate Therapeutics position peaked at $176K in Q2 2019.
  • 149 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.